Schedule of Pharmaceutical Benefits - 1 December 2020 update

1 December 2020 - The December 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...

Read more →

Canada bans mass exports of prescription drugs

29 November 2020 - Canada has banned the export of some prescription medicines in order to prevent a shortage in ...

Read more →

Sudden epilepsy deaths: grieving mum speaks out ahead of coronial inquest

28 November 2020 - Michelle Townes believes her 31-year-old son died because the brand of his Government funded drug was switched.  ...

Read more →

Drug change not ruled out as factor in epilepsy death, neurologist's report says

29 November 2020 - The first official recognition that changing brands of epilepsy drugs may have been a factor in at ...

Read more →

Key PBS listing to save Australians with severe back and neck pain more than 20,000 dollars

29 November 2020 - Thousands of Australians with debilitating back and joint pain will have access to a life changing treatment ...

Read more →

Will COVID-19 vaccines be cost effective—and does it matter?

26 November 2020 - The costs of other pandemic measures mean that covid-19 vaccines will probably turn out to be ...

Read more →

First jabs could take place within days in the UK

29 November 2020 - A COVID-19 vaccine could be rolled out in the UK within days, with reports approval of ...

Read more →

PBS support for Australians living with leukaemia

28 November 2020 - Patients living with one of Australia’s most common forms of leukaemia are set to benefit from expanded ...

Read more →

Alnylam announces innovative value-based agreement framework for Oxlumo (lumasiran) to accelerate access for patients with primary hyperoxaluria type 1 and deliver ultra-rare orphan disease pricing solutions to U.S. payers

24 November 2020 - Expedited access to Oxlumo aims to support children and adults living with PH1 who face inevitable disease ...

Read more →

Vertex announces European Commission approval for Symkevi (tezacaftor/ivacaftor) with Kalydeco (ivacaftor) for eligible children with cystic fibrosis ages 6-11 years

27 November 2020 - The combination therapy is a new treatment option for CF patients who are homozygous for F508del. ...

Read more →

Polaryx Therapeutics receives both rare paediatric disease and orphan drug designations for the treatment of GM2 gangliosidosis with PLX-300

25 November 2020 - Polaryx Therapeutics announced today that it has received from the U.S. FDA both rare paediatric disease and ...

Read more →

FDA approves first treatment for weight management for people with certain rare genetic conditions

27 November 2020 - The U.S. FDA has approved Imcivree (setmelanotide) for chronic weight management (weight loss and weight maintenance for ...

Read more →

Protalix BioTherapeutics and Chiesi Global Rare Diseases announce extension of PDUFA date for pegunigalsidase alfa for the proposed treatment of Fabry disease

27 November 2020 - Protalix BioTherapeutics today announced that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) ...

Read more →

Global regulators urge continuation of COVID-19 vaccine trials for longer-term safety and efficacy follow-up

27 November 2020 - EMA has endorsed a statement by the International Coalition of Medicines Regulatory Authorities that urges all stakeholders, ...

Read more →

Dr Crawshaw takes over as PHARMAC’s medical director after COVID challenges in the UK

27 November 2020 - PHARMAC is pleased to announce that Dr Shirley Crawshaw, seven months after she was appointed, has arrived ...

Read more →

Proposal for funded multiple sclerosis treatments

27 November 2020 - PHARMAC is proposing some changes to the way that multiple sclerosis treatments are funded, as well ...

Read more →